Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-aminopyridine in chronic spinal cord injury
NCT03899584Phase 3Unknown
- Sponsor
- Coordinación de Investigación en Salud
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal cord injury (SCI) comparing Treatment with 4-aminopyridine with Placebo oral capsule (2 arms). Primary endpoints: Changes in Sensory Function at 24 weeks, Changes in Motor Function at 24 weeks and 5 more. Status: unknown.
02
Drugs
dalfampridine
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT03899584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899584.